Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company has continued to show high growth and profitability, with a strong focus on brand promotion, market education, and product development [6][2] - The company plans to purchase land use rights to enhance its R&D and production capabilities, which is expected to solidify its competitive advantages [6] - The company is projected to achieve significant revenue and profit growth over the next few years, with expected revenues of 14.83 billion, 20.06 billion, and 25.69 billion for 2024, 2025, and 2026 respectively [6] Financial Performance Summary - For the first three quarters of 2024, the company reported revenue of 988 million (up 91.2% YoY) and net profit attributable to shareholders of 520 million (up 170.4% YoY) [6] - In Q3 2024, the company achieved revenue of 386 million (up 92.1% YoY) and net profit of 210 million (up 154.0% YoY) [6] - The gross margin for Q3 2024 was 93.6% (up 2.35 percentage points YoY), with a net profit margin of 54.57% (up 13.3 percentage points YoY) [6][2] Financial Forecast - Revenue projections for 2024, 2025, and 2026 are 14.83 billion, 20.06 billion, and 25.69 billion respectively, with growth rates of 90.0%, 35.3%, and 28.1% [6] - Net profit projections for the same years are 7.57 billion, 10.45 billion, and 13.42 billion, with growth rates of 152.6%, 38.1%, and 28.4% [6] - Earnings per share (EPS) are expected to be 8.56, 11.81, and 15.16 for 2024, 2025, and 2026 respectively [6]
锦波生物：高成长、高盈利延续，研发壁垒持续夯实